<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="218403">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00241358</url>
  </required_header>
  <id_info>
    <org_study_id>03-0349</org_study_id>
    <nct_id>NCT00241358</nct_id>
  </id_info>
  <brief_title>Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies</brief_title>
  <official_title>A Phase I/II Study Evaluating the Safety and Efficacy of AMD3100 for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Patients With Advanced Hematological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if peripheral blood cells collected following
      AMD3100 mobilization can be used safely for hematopoietic cell transplantation into
      HLA-matched recipients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will determine if peripheral blood cells collected following AMD3100 mobilization
      can be used safely for hematopoietic cell transplantation into HLA-matched recipients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of donors from whom a sufficient number of cells for transplantation are collected in no more than 2 LP procedures following mobilization with AMD3100</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of recipients who experience grade 2-4 acute GVHD</measure>
    <time_frame>Day 100</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of recipients who successfully engraft by day +21 after transplant</measure>
    <time_frame>Day 21 after transplant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of recipients who experience chronic GVHD (any grade)</measure>
    <time_frame>12 months after transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent recipient mortality at day 100 after transplant</measure>
    <time_frame>100 days after transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life during stem cell mobilization</measure>
    <time_frame>48-72 hours after last dose of AMD3100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicities during mobilization</measure>
    <time_frame>30 days after completion of AMD3100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of SC and IV AMD3100</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Leukemia, Myeloid, Acute</condition>
  <condition>Leukemia, Myelogenous, Chronic</condition>
  <condition>Leukemia, Lymphoblastic, Acute</condition>
  <condition>Lymphocytic Leukemia, Chronic</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <condition>Hodgkin Disease</condition>
  <arm_group>
    <arm_group_label>Subcutaneous (SC) Treatment Plan - Donor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AMD3100 SC 240 ug/kg/actual donor weight on Day 1 and possibly Day 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous Treatment Plan - Donor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients 21-39 will receive IV AMD3100 according to cohorts on day -3 (80 ug/kg cohort 1, 160 ug/kg cohort 2, 240 ug/kg cohort 3, 320 ug/kg cohort 4, 400 ug/kg cohort 5, 480 ug/kg cohort 6) and SC AMD3100 240 ug/kg/actual donor weight on day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Recepients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Stem Cell Transplantation Day 0</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMD3100</intervention_name>
    <arm_group_label>Subcutaneous (SC) Treatment Plan - Donor</arm_group_label>
    <arm_group_label>Intravenous Treatment Plan - Donor</arm_group_label>
    <other_name>Plerixafor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem Cell Transplant</intervention_name>
    <arm_group_label>Recepients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Donor criteria:

          -  Donor is 18 to 70 years of age inclusive

          -  If female and of child-bearing age, must be:

               -  non-pregnant,

               -  not breast feeding and

               -  using adequate contraception

          -  Donor is a 6/6 HLA-matched sibling willing to donate peripheral blood stem cell for
             transplant

          -  Donor must be willing to provide written informed consent.

          -  Adequate cardiac function with no history of congestive heart failure and no history
             of atrial fibrillation or ventricular tachyarrhythmia.

          -  Adequate renal function as defined by a serum creatinine clearance of ≥75% of normal
             (Cockcroft-Gault equation)

          -  Adequate hepatic function as defined by a total bilirubin &lt;2x normal or absence of
             hepatic fibrosis/cirrhosis

          -  Adequate neurologic function as defined by:

               -  No evidence of a severe central or peripheral neurologic abnormality.

               -  No history of cerebrovascular accident or seizure disorder requiring
                  anticonvulsant medication

          -  Must be HIV-1 &amp; 2 antibody, HIV-1 antigen, and HTLV-I &amp; II antibody sero-negative, by
             FDA licensed test.

          -  Must have an ECOG performance status of 0 or 1

          -  Must demonstrate ability to be compliant with study regimen.

          -  Must not have an active infection at the time of study entry

          -  Not have active alcohol or substance abuse within 6 months of study entry

          -  Not currently enrolled in another investigational agent study

          -  Not have any medical condition, which, in the opinion of the clinical investigator,
             would interfere with his/her evaluation

        Recipient criteria:

          -  18 to 65 years of age inclusive

          -  Willing and has a 6/6 HLA-matched sibling willing to donate PBSC for transplant

          -  Provide signed informed consent

          -  If female and of child-bearing age, must be:

               -  non-pregnant,

               -  not breast feeding, and

               -  using adequate contraception

        Patient must have one of the following diagnoses:

          -  AML in 1st or subsequent remission or in relapse

          -  ALL in 1st or subsequent remission or in relapse

          -  MDS and intermediate 1 or 2, or high risk by the International Prognostic Scoring
             System

          -  CML in accelerated or second chronic phase

          -  NHL or HD in 2nd or greater complete remission, partial remission,or refractory
             relapse

          -  CLL Rai Stage 2-4, failing at least 2 prior regimens

          -  MM Stage 2-3

          -  Adequate cardiac function with a left ventricular ejection fraction ≥ 40%

          -  Adequate pulmonary function defined as:

               -  No severe or symptomatic restrictive or obstructive lung disease, and

               -  formal pulmonary function testing showing an forced expiratory volume at 1
                  second (FEV1) ≥50% of predicted and a diffusion capacity of the lung for carbon
                  monoxide (DLCO) ≥40% of predicted, corrected for hemoglobin

          -  Adequate renal function as defined by a serum creatinine clearance of ≥75% of normal
             (Cockcroft-Gault equation)

          -  Adequate hepatic function as defined by a total bilirubin &lt;2x normal or absence of
             hepatic fibrosis/cirrhosis

          -  Adequate neurologic function as defined by no evidence of a severe central or
             peripheral neurologic abnormality. Patients with a history of previous central
             nervous system tumor involvement are eligible provided they are without symptoms or
             signs and the CNS is now free of disease on lumbar puncture and CT scan of the brain

          -  No evidence of active infection at the time of the transplant preparative regimen or
             at the time of transplantation

          -  Patient must be HIV-1 &amp; 2 antibody, HIV-1 antigen, and HTLV-I &amp; II antibody
             sero-negative, by FDA licensed test

          -  ECOG performance status of 0 or 1

          -  Must demonstrate ability to be compliant with medical regimen

          -  Not have active alcohol or substance abuse within 6 months of study entry

          -  Not be concurrently enrolled on another study involving an investigational agent

          -  Not have any medical condition, which, in the opinion of the clinical investigator,
             would interfere with the evaluation of the patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John F. DiPersio, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <reference>
    <citation>Devine SM, Vij R, Rettig M, Todt L, McGlauchlen K, Fisher N, Devine H, Link DC, Calandra G, Bridger G, Westervelt P, Dipersio JF. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood. 2008 Aug 15;112(4):990-8. doi: 10.1182/blood-2007-12-130179. Epub 2008 Apr 21.</citation>
    <PMID>18426988</PMID>
  </reference>
  <reference>
    <citation>Devine SM, Flomenberg N, Vesole DH, Liesveld J, Weisdorf D, Badel K, Calandra G, DiPersio JF. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol. 2004 Mar 15;22(6):1095-102.</citation>
    <PMID>15020611</PMID>
  </reference>
  <reference>
    <citation>Flomenberg N, Devine SM, Dipersio JF, Liesveld JL, McCarty JM, Rowley SD, Vesole DH, Badel K, Calandra G. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood. 2005 Sep 1;106(5):1867-74. Epub 2005 May 12.</citation>
    <PMID>15890685</PMID>
  </reference>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 9, 2013</lastchanged_date>
  <firstreceived_date>October 17, 2005</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Plerixafor</keyword>
  <keyword>Stem cell transplantation</keyword>
  <keyword>Stem cells</keyword>
  <keyword>Mobilization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>JM 3100</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
